Related references
Note: Only part of the references are listed.Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2020)
Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
Jordan E. Lake et al.
CLINICAL INFECTIOUS DISEASES (2020)
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017
Mario Gomez et al.
INFECTION (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
David A. Wohl et al.
LANCET HIV (2019)
Dolutegravir monotherapy and body weight gain in antiretroviral naive patients
Sebastiano Rizzardo et al.
AIDS (2019)
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
David R. Bakal et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
Anthony T. Podany et al.
CLINICAL PHARMACOKINETICS (2017)
Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens
Jamison Norwood et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Dolutegravir and weight gain: an unexpected bothering side effect?
Amelie Menard et al.
AIDS (2017)
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
John R. Koethe et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals
Melissa Herrin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults
Vidya Mave et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Weight Change After Antiretroviral Therapy and Mortality
Bianca Yuh et al.
CLINICAL INFECTIOUS DISEASES (2015)
Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection
Tae Eun Park et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation
Fred R. Sattler et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Impact of randomized antiretroviral therapy initiation on glucose metabolism
Kristine Mace Erlandson et al.
AIDS (2014)
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
Kristine M. Erlandson et al.
AIDS (2013)
Short Communication From Wasting to Obesity: Initial Antiretroviral Therapy and Weight Gain in HIV-Infected Persons
Wanda Lakey et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
HIV Infection and the Risk of Acute Myocardial Infarction
Matthew S. Freiberg et al.
JAMA INTERNAL MEDICINE (2013)
Multimorbidity Patterns in HIV-Infected Patients: The Role of Obesity in Chronic Disease Clustering
David J. Kim et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Association Between Weight Gain and Clinical Outcomes Among Malnourished Adults Initiating Antiretroviral Therapy in Lusaka, Zambia
John R. Koethe et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries
Yoann Madec et al.
AIDS (2009)